Fast Track designation - Denmark

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Read More

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

2026-04-29

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is…

Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price

Read More

Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price

2026-04-28

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…

Novo Nordisk updates DKK 15B share buyback | NVO SEC Filing

Read More

Novo Nordisk’s etavopivat hits phase 3 goals in SCD | NVO SEC Filing

2026-04-20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…